Covid fatigue takes toll on vaccine makers
Demand for boosters falls as virus seen as something less to be feared than managed
Investing. Plain and simple.
Demand for boosters falls as virus seen as something less to be feared than managed
Considered dull during the tech boom, these mature, global businesses are back in favour.
It should be another good year, but share prices may have limited upside.
Drug companies have won praise for a quick rollout of COVID vaccines. Are investors also winners?